tradingkey.logo

Cognition Therapeutics Study Of Zervimesine (CT1812) In Early Alzheimer’s Disease Surpasses 50% Enrollment Target

ReutersJul 1, 2025 11:32 AM

- Cognition Therapeutics Inc CGTX.O:

  • COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET

  • COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET

  • COGNITION THERAPEUTICS INC - PHASE 2 SHINE STUDY SHOWS 38% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE

  • COGNITION THERAPEUTICS INC - LOWER P-TAU217 LEVELS SHOW 95% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE

  • COGNITION THERAPEUTICS INC - START STUDY RECEIVES $81 MILLION GRANT SUPPORT FROM NIA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI